Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
All content for Being a Life Sciences Leader is the property of Life Sciences Pennsylvania and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
John Crowley, Hubert J.P. Schoemaker Leadership Award
Being a Life Sciences Leader
29 minutes
1 year ago
John Crowley, Hubert J.P. Schoemaker Leadership Award
In this episode, John Crowley, recipient of the 2024 Hubert J.P. Schoemaker Leadership Award, discusses how his children's diagnosis of a rare disease altered his career path to becoming a leader in the life sciences. Learn more about John's motivation to improve the lives of patients through his new role as President & CEO at BIO.
Being a Life Sciences Leader
Tune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.
